Inhalation Drugs

Janssen’s Spravato (esketamine) gains approval with restricted distribution guidelines.

Copley Scientific-a manufacturer and provider of test instrumentations for pharmaceutical dosage forms-has officially opened its newly expanded headquarters in Colwick, United Kingdom.

The agency approved Insmed’s Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease).

Guenter Nadler, director of Business Development at Aptar Pharma, will present an insight briefing on new drug-delivery trends in treating upper and lower respiratory tract issues on Wednesday, Oct. 9, 2018 at CPhI Worldwide.

Emergent BioSolutions is set to acquire Adapt Pharma, a pharmaceutical company focused on addressing the opioid overdose and addiction crisis, in a deal worth up to $735 million.

The purchase of Novartis’ cystic fibrosis products TOBI Podhaler and TOBI solution is expected to strengthen Mylan’s global respiratory portfolio.

Formulation characteristics must be optimized, following device selection, to achieve the desired performance for the capsule loaded in the dry powder inhaler.

Recipharm adds inhalation drug manufacturing capacity with the acquisition of Sanofi’s Holmes Chapel, UK site.

Choice of carrier can have a significant impact on the capsule filling process as well as the performance of the DPI formulation.

Particle engineering using jet milling or spray drying can be used to obtain appropriate particle characteristics for inhalation drug products.

Aston Particle Technologies has developed a technology that produces functionalized particles in a one-step, environmentally friendly process.

Hovione has installed a new MG2 Tekna Precision Capsule filler at its Portugal site.

Considerations in selecting a dosage form for drug delivery to the lungs.

Pulmonary drug delivery is becoming increasingly used. When developing pulmonary drugs, pharmaceutical chemists must consider drug absorption, control of particle size, suitable toxicology models, and patient compliance. The author reviews the issues specific to developing drugs designed for pulmonary delivery and considers how-with the right knowledge and expertise-these challenges can be overcome.

Successful development requires coordinating and aligning drug and device design, focusing on a complete drug delivery system that meets patients’ needs.

Follow guidelines for E&L studies of an orally inhaled and nasal drug product formulation in its delivery device.

The Intelligent Control Inhaler is an intuitive, fully-integrated device delivering accurate doses of medication to patients, while providing on-screen instructions for use and feedback to the patient and healthcare provider via an app.

Understanding the components of a reference marketed pMDI is needed to develop a generic pMDI.

Successful drug delivery via a dry powder inhaler is determined by the API physicochemical properties, the formulation composition and process, the device and operating conditions, the patient–device relationship, the environmental variables, and ultimately, patient compliance.

Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.

The role of add-on devices and how they affect drug delivery with a pressurized metered dose inhaler.

Experts discuss factors affecting drug delivery to the lungs and key considerations when developing inhalation formulations.

Products enable testing in accordance with methods described in new USP monograph.

In this sponsored podcast, Adam Stuart, Senior Design Engineer at 3M Drug Delivery Systems, discusses the role of dose counters for metered dose inhalers and the technical challenges companies can face when adding this feature to their inhaler products.

Intertek is now offering comprehensive services for the development of orally inhaled and intranasal drug products (OINDPs) for both small molecules and biologics.